AI models can modify the genetic sequences of known bioweapons like ricin just enough to evade current screening protocols at DNA synthesis companies. This creates functional but 'obfuscated' threats, demonstrating a critical vulnerability in our biodefense supply chain.

The ability to distinguish an engineered virus from a natural one is a critical deterrent. Proving a pathogen was deliberately created narrows the list of suspects to a handful of state programs, enabling political and intelligence-led responses that would otherwise be impossible.

The danger of AI creating harmful proteins is not in the digital design but in its physical creation. A protein sequence on a computer is harmless. The critical control point is the gene synthesis process. Therefore, biosecurity efforts should focus on providing advanced screening tools to synthesis providers.

Instead of trying to control open-source AI models, which is intractable, the proposed strategy is to control the small, expensive-to-produce functional datasets they train on. This preserves the beneficial open-source ecosystem while preventing the dissemination of dangerous capabilities like viral design.

Current biosecurity screens for threats by matching DNA sequences to known pathogens. However, AI can design novel proteins that perform a harmful function without any sequence similarity to existing threats. This necessitates new security tools that can predict a protein's function, a concept termed "defensive acceleration."

Unlike nuclear deterrence, there is no single theory of victory for biosecurity. The most effective approach is a layered strategy combining four pillars: Delay (e.g., data controls), Deter (e.g., treaties), Detect (e.g., wastewater monitoring), and Defend (e.g., far-UV sterilization).

Polygenic embryo screening, while controversial, presents a clear economic value proposition. A $3,500 test from Genomic Prediction that lowers Type 2 Diabetes risk by 12% implies that avoiding the disease is worth over $27,000. This reframes the service from 'designer babies' to a rational financial decision for parents.

U.S. FDA requirements for early-stage trials, particularly safety margins, are considered ill-suited for genetic medicines, prompting companies to look abroad. The UK is emerging as a preferred destination, with its regulator, the MHRA, actively creating incentives and faster pathways to attract these innovative clinical programs.

While 80% of DNA synthesis companies voluntarily screen orders for dangerous pathogen sequences, the system is not mandatory. This creates a glaring loophole, as a malicious actor can simply place their order with the 20% of companies that do not perform this critical safety check.